64Cu-PSMA-BCH:一种用于前列腺癌延迟PET成像的新型放射性示踪剂
本研究开发了64Cu标记的靶向PSMA的放射性药物64Cu-PSMA-BCH,并评估其稳定性、PSMA特异性及micro-PET成像,随后在4例疑似前列腺癌患者中进行PET/CT成像和辐射剂量估算,并对3例患者行PSMA PET-超声引导活检。结果显示该示踪剂放射化学产率高、稳定性好,延迟成像可提高肿瘤摄取和T/N比,有助于检测小病灶和指导靶向活检,全身有效剂量为0.0292 mSv/MBq。
要点
- 64Cu-PSMA-BCH放射化学产率高、稳定性好,具有PSMA特异性。
- 延迟成像(6 h和24 h)较1 h检测到更多肿瘤病灶。
- 全身有效剂量为0.0292 mSv/MBq,胆囊壁为最关键器官。
核心结论
- 64Cu-PSMA-BCH具有PSMA特异性且体内稳定性高,肝脏摄取低于64Cu-PSMA-617。
- 小鼠和前列腺癌患者的生物分布与其他PSMA配体相似,安全性好且有效剂量适中。
- 延迟成像增加的肿瘤摄取和T/N比可能有助于检测小病灶和指导靶向活检。
研究设计与样本
- 制备64Cu-PSMA-BCH并研究其稳定性、PSMA特异性和micro-PET成像。
- 经北京癌症医院伦理委员会批准(编号2017KT97),对4例疑似前列腺癌患者行PET/CT成像并估算辐射剂量。
- 对3例患者行PSMA PET-超声图像引导活检,并对细针穿刺样本行放射自显影和免疫组化分析。
主要发现
- 64Cu-PSMA-BCH以高放射化学产率和稳定性制备。
- 体内研究显示PSMA(+)22Rv1细胞摄取高于PSMA(-)PC-3细胞(1 h时为5.59 ± 0.36和1.97 ± 0.22 IA%/106细胞)。
- 注射后1至24 h,22Rv1肿瘤中放射性摄取和T/N比逐渐增加。
- 疑似前列腺癌患者注射后24 h内SUVmax和T/N比升高;与1 h图像相比,6 h和24 h检测到更多肿瘤病灶。
- 人器官辐射剂量学显示胆囊壁为最关键器官,肝脏和肾脏次之,全身有效剂量为0.0292 mSv/MBq。
临床怎么用
- 可利用64Cu-PSMA-BCH延迟PET成像提高前列腺癌小病灶检出率。
- 该示踪剂可指导PSMA PET-超声引导靶向活检。
- 辐射剂量学数据支持其临床安全性,胆囊壁为关键器官。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Develop a 64Cu labeled radiopharmaceutical targeting prostate specific membrane antigen (PSMA) and investigate its application for prostate cancer imaging. METHODS: 64Cu-PSMA-BCH was prepared and investigated for stability, PSMA specificity, and micro-PET imaging. With the approval of Ethics Committee of Beijing Cancer Hospital (No. 2017KT97), PET/CT imaging in 4 patients with suspected prostate cancer was performed and the radiation dosimetry was estimated. Then, PSMA PET-ultrasound image-guided biopsies were performed on 3 patients and the fine needle aspirates were further performed for autoradiography and immunohistochemistry analysis. RESULTS: 64Cu-PSMA-BCH was prepared with high radiochemical yield and stability. In vivo study showed higher uptake in PSMA ( +) 22Rv1 cells than PSMA ( -) PC-3 cells (5.59 ± 0.36 and 1.97 ± 0.22 IA%/106 cells at 1 h). It accumulated in 22Rv1 tumor with increasing radioactivity uptake and T/N ratios from 1 to 24 h post-injection. In patients with suspected prostate cancer, SUVmax and T/N ratios increased within 24 h post-injection. Compared with image at 1 h post-injection, more tumor lesions were detected at 6 h and 24 h post-injection. The human organ radiation dosimetry showed gallbladder wall was most critical, liver and kidneys were followed, and the whole-body effective dose was 0.0292 mSv/MBq. Two fine needle aspirates obtained by PET-ultrasound-guided targeted biopsy showed high radioactive signal by autoradiography, with 100% PSMA expression in cytoplasm and 30% expression in nucleus. CONCLUSION: 64Cu-PSMA-BCH was PSMA specific and showed high stability in vivo with lower uptake in liver than 64Cu-PSMA-617. Biodistribution in mice and PCa patients showed similar profile compared with other PSMA ligands and it was safe with moderate effective dosimetry. The increased tumor uptake and T/N ratios by delayed imaging may facilitate the detection of small lesions and guiding targeted biopsies.
引用
- Liu T, Liu C, Zhang Z, et al. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34170361. doi:10.1007/s00259-021-05426-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。